Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK. Issue 11 (9th April 2020)

• Record Type: Journal Article
• Authors: Crowe, Francesca; Zemedikun, Dawit T; Okoth, Kelvin; Adderley, Nicola Jaime; Rudge, Gavin; Sheldon, Mark; Nirantharakumar, Krishnarajah; Marshall, Tom
• Is Part Of: Heart. Volume 106:Issue 11(2020)
• Page Start: 810
• Page End: 816
• Publication Date: 2020-04-09
• Subjects: comorbidity -- ischaemic heart disease -- latent class analysis -- mortality -- the health improvement network; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2019-316091
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objectives: The objective of this study is to use latent class analysis of up to 20 comorbidities in patients with a diagnosis of ischaemic heart disease (IHD) to identify clusters of comorbidities and to examine the associations between these clusters and mortality. Methods: Longitudinal analysis of electronic health records in the health improvement network (THIN), a UK primary care database including 92 186 men and women aged ≥18 years with IHD and a median of 2 (IQR 1–3) comorbidities. Results: Latent class analysis revealed five clusters with half categorised as a low-burden comorbidity group. After a median follow-up of 3.2 (IQR 1.4–5.8) years, 17 645 patients died. Compared with the low-burden comorbidity group, two groups of patients with a high-burden of comorbidities had the highest adjusted HR for mortality: those with vascular and musculoskeletal conditions, HR 2.38 (95% CI 2.28 to 2.49) and those with respiratory and musculoskeletal conditions, HR 2.62 (95% CI 2.45 to 2.79). Hazards of mortality in two other groups of patients characterised by cardiometabolic and mental health comorbidities were also higher than the low-burden comorbidity group; HR 1.46 (95% CI 1.39 to 1.52) and 1.55 (95% CI 1.46 to 1.64), respectively. Conclusions: This analysis has identified five distinct comorbidity clusters in patients with IHD that were differentially associated with risk of mortality. These analyses should be replicated in other large datasets, and this may help shape the development of future interventions or health services that take into account the impact of these comorbidity clusters.